Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Portfolio News / By admin March 5, 2020 Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Read More »
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo Portfolio News / By admin February 24, 2020 NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo Read More »
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By admin February 18, 2020 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
Revolution Medicines Announces Pricing of Initial Public Offering Portfolio News / By admin February 12, 2020 Revolution Medicines Announces Pricing of Initial Public Offering Read More »
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) Portfolio News / By admin February 11, 2020 NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) Read More »
RAPT Therapeutics Announces Pricing of $75 Million Public Offering Portfolio News / By admin February 7, 2020 RAPT Therapeutics Announces Pricing of $75 Million Public Offering Read More »
ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with Astellas Portfolio News / By admin January 27, 2020 ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with Astellas Read More »
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference Portfolio News / By admin January 13, 2020 Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference Read More »
Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies Portfolio News / By admin January 6, 2020 Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies Read More »
Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers Portfolio News / By admin December 18, 2019 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers Read More »
